Recently, studies from our laboratory identified the upregulation of Nrf2 in malignant breast carcinomas and demonstrated that the targeted inhibition of Nrf2-sensitized cancer cells to chemotherapeutic agents (Bovilla et al., unpublished results). The gene discussed is NFE2L2; the disease is cancer.